ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LM-364

A development code. Also written as “LM-364 for injection”.

Its studies are mostly in Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 2, since Jul 3, 20262 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical22 open or runningphase 2since Jul 3, 2026Jul 3, 2026Dec 31, 2028phase 2 · NCT07694765

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 3, 2026First study: phase 2 study in NeoplasmsFirst studyNCT07694765 · 90 planned · Australia
  2. Sep 23, 2026Phase 2 study in Advanced Solid Tumor CancerNCT07847905 · 90 planned · China

Ahead

  1. Dec 31, 2028Primary completion: phase 2 study in NeoplasmsNCT07694765
  2. Oct 19, 2030Primary completion: phase 2 study in Advanced Solid Tumor CancerNCT07847905

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07847905Advanced Solid Tumor Cancer · China2By invitationOct 19, 203090
NCT07694765Neoplasms · Australia2Not yet recruitingDec 31, 202890

How it is read

Names in the registry

  • “LM-364 for injection”, 2 entries

Codes read as this program: LM364.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.